Substance p upregulates cyclooxygenase-2 and prostaglandin E metabolite by activating ERK1/2 and NF-κB in a mouse model of burn-induced remote Acute lung injury

Journal of Immunology

Volumn 185, Issue 10, 2010, Pages 6265-6276

  Sio, Selena W S ^a   Ang, Seah Fang ^b   Lu, Jia ^c   Moochhala, Shabbir ^a,c   Bhatia, Madhav ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DSO NATIONAL LABORATORIES   (Singapore)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 BENZHYDRYL 3 (2 IODOBENZYLAMINO)QUINUCLIDINE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NEUROKININ; PARECOXIB; PREPROTACHYKININ A; PROSTAGLANDIN E; SUBSTANCE P; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; BODY SURFACE; BURN; CONTROLLED STUDY; ENZYME ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

ACUTE LUNG INJURY; ANIMALS; BLOTTING, WESTERN; BURNS; CHEMOKINES; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; PROSTAGLANDINS E; SIGNAL TRANSDUCTION; SUBSTANCE P; UP-REGULATION;

EID: 78650664731     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001739     Document Type: Article

References (78)

1. Marko, P., A. J. Layon, L. Caruso, D. W. Mozingo, and A. Gabrielli. 2003. Burn injuries. Curr. Opin. Anaesthesiol. 16:183-191.
2. Turnage, R. H., F. Nwariaku, J. Murphy, C. Schulman, K. Wright, and H. Yin. 2002. Mechanisms of pulmonary microvascular dysfunction during severe burn injury. World J. Surg. 26:848-853.
3. Nishimura, N., and N. Hiranuma. 1982. Respiratory changes after major burn injury. Crit. Care Med. 10:25-28.
4. Saffle, J. R., J. J. Sullivan, G. M. Tuohig, and C. M. Larson. 1993. Multiple organ failure in patients with thermal injury. Crit. Care Med. 21:1673-1683.
5. Sheridan, R. L., C. M. Ryan, L. M. Yin, J. Hurley, and R. G. Tompkins. 1998. Death in the burn unit: sterile multiple organ failure. Burns 24:307-311.
6. Rodriguez, J. L., C. G. Miller, W. L. Garner, G. O. Till, P. Guerrero, N. P. Moore, M. Corridore, D. P. Normolle, D. J. Smith, and D. G. Remick. 1993. Correlation of the local and systemic cytokine response with clinical outcome following thermal injury. J. Trauma 34:684-694, discussion 694-695.
7. Arturson, G. 1996. Pathophysiology of the burn wound and pharmacological treatment: the Rudi Hermans Lecture, 1995. Burns 22:255-274.
8. Wheeler, A. P., and G. R. Bernard. 2007. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 369:1553-1564.
9. O'Connor, T. M., J. O'Connell, D. I. O'Brien, T. Goode, C. P. Bredin, and F. Shanahan. 2004. The role of substance P in inflammatory disease. J. Cell. Physiol. 201:167-180.
10. Groneberg, D. A., S. Harrison, Q. T. Dinh, P. Geppetti, and A. Fischer. 2006. Tachykinins in the respiratory tract. Curr. Drug Targets 7:1005-1010.
11. Sio, S. W., S. Moochhala, J. Lu, and M. Bhatia. 2010. Early protection from burn-induced acute lung injury by deletion of preprotachykinin-A gene. Am. J. Respir. Crit. Care Med. 181:36-46.
12. Sio, S. W., M. K. Puthia, J. Lu, S. Moochhala, and M. Bhatia. 2008. The neuropeptide substance P is a critical mediator of burn-induced acute lung injury. J. Immunol. 180:8333-8341.
13. Funk, C. D. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871-1875.
14. Hinz, B., and K. Brune. 2002. Cyclooxygenase-2:10 years later. J. Pharmacol. Exp. Ther. 300:367-375.
15. Fukunaga, K., P. Kohli, C. Bonnans, L. E. Fredenburgh, and B. D. Levy. 2005. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 174:5033-5039.
16. 2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology 13:1014-1021.
17. Lappi-Blanco, E., R. Kaarteenaho-Wiik, P. K. Maasilta, S. Anttila, P. Pääkkö, and H. J. Wolff. 2006. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am. J. Clin. Pathol. 126:717-724.
18. Carpagnano, G. E., A. Spanevello, G. P. Palladino, C. Gramiccioni, C. Ruggieri, F. Carpagnano, and M. P. Foschino Barbaro. 2009. Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link? Lung Cancer 67:108-113.
19. Koon, H. W., D. Zhao, Y. Zhan, S. H. Rhee, M. P. Moyer, and C. Pothoulakis. 2006. Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J. Immunol. 176:5050-5059.
20. Gallicchio, M., A. C. Rosa, E. Benetti, M. Collino, C. Dianzani, and R. Fantozzi. 2006. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. Br. J. Pharmacol. 147:681-689.
21. Gallicchio, M., E. Benetti, A. C. Rosa, and R. Fantozzi. 2009. Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. Br. J. Pharmacol. 156:486-496.
22. Szarek, J. L., B. Spurlock, C. A. Gruetter, and S. Lemke. 1998. Substance P and capsaicin release prostaglandin E2 from rat intrapulmonary bronchi. Am. J. Physiol. 275: L1006-L1012.
23. Devillier, P., G. M. Acker, C. Advenier, J. Marsac, D. Regoli, and N. Frossard. 1992. Activation of an epithelial neurokinin NK-1 receptor induces relaxation of rat trachea through release of prostaglandin E2. J. Pharmacol. Exp. Ther. 263:767-772.
24. 2. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L469-L474.
25. Stevenson, J. M., R. L. Gamelli, and R. Shankar. 2003. Wound Healing: Methods and Protocols (Methods in Molecular Medicine). Humana Press Inc, Totowa, NJ.
26. Cao, Y. Q., P. W. Mantyh, E. J. Carlson, A. M. Gillespie, C. J. Epstein, and A. I. Basbaum. 1998. Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392:390-394.
27. Francis, B. E., C. Swain, V. Sabin, and H. D. Burns. 1994. Radioiodinated L-703, 606: a potent, selective antagonist to the human NK1 receptor. Appl. Radiat. Isot. 45:97-103.
28. Cascieri, M. A., E. Ber, T. M. Fong, S. Sadowski, A. Bansal, C. Swain, E. Seward, B. Frances, D. Burns, and C. D. Strader. 1992. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor. Mol. Pharmacol. 42:458-463.
29. Teagarden, D. L., and N. Sandeep. 2007. Case study: parecoxib: a prodrug of valdecoxib. In Prodrugs: Challenges and Rewards (Part 1, Biotechnology: Pharmaceutical Aspects). V. J. Stella, R. T. Borchardt, M. J. Hageman, R. Oliyai, H. Maag, and J. W. Tilley, eds. Springer, New York, p. 1335-1346.
30. Padi, S. S., N. K. Jain, S. Singh, and S. K. Kulkarni. 2004. Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur. J. Pharmacol. 491:69-76.
31. Talley, J. J., S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, M. S. Kellogg, C. M. Koboldt, J. Yuan, Y. Y. Zhang, and K. Seibert. 2000. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43:1661-1663.
32. Alessi, D. R., A. Cuenda, P. Cohen, D. T. Dudley, and A. R. Saltiel. 1995. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270:27489-27494.
33. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686-7689.
34. Zhang, H., S. M. Moochhala, and M. Bhatia. 2008. Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis. J. Immunol. 181:4320-4331.
35. Minutoli, L., P. Antonuccio, C. Romeo, P. A. Nicòtina, A. Bitto, S. Arena, F. Polito, D. Altavilla, N. Turiaco, A. Cutrupi, et al. 2005. Evidence for a role of mitogen-activated protein kinase 3/mitogen-activated protein kinase in the development of testicular ischemia-reperfusion injury. Biol. Reprod. 73:730-736.
36. Di Paola, R., C. Crisafulli, E. Mazzon, T. Genovese, I. Paterniti, P. Bramanti, and S. Cuzzocrea. 2009. Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice. Int. J. Immunopathol. Pharmacol. 22:937-950.
37. 2-agonist in mice. Chest 126:205-212.
38. Clemons, A. P., D. M. Holstein, A. Galli, and C. Saunders. 2002. Ceruleininduced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059. Pancreas 25:251-259.
39. Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins, and M. E. Gerritsen. 1997. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272:21096-21103.
40. Zhang, H., L. Zhi, S. M. Moochhala, P. K. Moore, and M. Bhatia. 2007. Endogenous hydrogen sulfide regulates leukocyte trafficking in cecal ligation and puncture-induced sepsis. J. Leukoc. Biol. 82:894-905.
41. Strohm, C., T. Barancik, M. L. Brühl, S. A. Kilian, and W. Schaper. 2000. Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J. Cardiovasc. Pharmacol. 36:218-229.
42. Malaver, E., M. A. Romaniuk, L. P. D'Atri, R. G. Pozner, S. Negrotto, R. Benzadón, and M. Schattner. 2009. NF-κB inhibitors impair platelet activation responses. J. Thromb. Haemost. 7:1333-1343.
43. Labarca, C., and K. Paigen. 1980. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102:344-352.
44. Pittet, J. F., R. C. Mackersie, T. R. Martin, and M. A. Matthay. 1997. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med. 155:1187-1205.
45. Zarbock, A., K. Singbartl, and K. Ley. 2006. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J. Clin. Invest. 116:3211-3219.
46. Mirakaj, V., C. A. Thix, S. Laucher, C. Mielke, J. C. Morote-Garcia, M. A. Schmit, J. Henes, K. E. Unertl, D. Köhler, and P. Rosenberger. 2010. Netrin-1 dampens pulmonary inflammation during acute lung injury. Am. J. Respir. Crit. Care Med. 181:815-824.
47. Hampton, M. B., A. J. Kettle, and C. C. Winterbourn. 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92:3007-3017.
48. Piper, P. J. 1974. Release and metabolism of prostaglandins in lung tissue. Pol. J. Pharmacol. Pharm. 26:61-72.
49. Piper, P. J., J. R. Vane, and J. H. Wyllie. 1970. Inactivation of prostaglandins by the lungs. Nature 225:600-604.
50. Wyllie, J. H., P. J. Piper, and J. R. Vane. 1969. Fate of prostaglandins in the lungs. Br. J. Surg. 56:623.
51. 2: the reason for low assay reliability. Prostaglandins 19:933-957.
52. 2: an indirect index of their in vivo disposition and pharmacokinetics. J. Pharmacol. Exp. Ther. 220:229-235.
53. Maclouf, J., J. Grassi, and P. Pradelles. 1987. Development of enzymeimmunoassay techniques for the measurement of eicosanoids. In Prostaglandin and Lipid Metabolism in Radiation Injury. T. L. J. Walden, and H. N. Hughes, eds. Plenum Press, Rockville, MD, p. 355-364.
54. Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807-869.
55. Wu, K. K. 1996. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J. Lab. Clin. Med. 128:242-245.
56. Krakauer, T. 2004. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-κB. Curr. Drug Targets Inflamm. Allergy 3:317-324.
57. 2 in lipopolysaccharide fever. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284: R698-R706.
58. 4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev. Res. (Phila. Pa.) 2:322-329.
59. 2, are increased in smokers. Clin. Cancer Res. 11:6087-6093.
60. Ohara, M., T. Sawa, K. Kurahashi, J. P. Wiener-Kronish, V. Doshi, I. Kudoh, and M. A. Gropper. 1998. Induction of cyclooxygenase-2 in alveolar macrophages after acid aspiration: selective cyclooxygenase-2 blockade reduces interleukin-6 production. Anesthesiology 88:1014-1022.
61. Cuzzocrea, S., E. Mazzon, L. Sautebin, L. Dugo, I. Serraino, A. de Sarro, and A. P. Caputi. 2002. Protective effects of celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem. Pharmacol. 63:785-795.
62. 2 in immune suppression following injury. Ann. Surg. 214:253-262, discussion 262-263.
63. Schwacha, M. G., A. Ayala, W. G. Cioffi, K. I. Bland, and I. H. Chaudry. 1999. Role of protein kinase C in cyclic AMP-mediated suppression of T-lymphocyte activation following burn injury. Biochim. Biophys. Acta 1455:45-53.
64. 2) in severely burned patients. Burns 22:298-302.
65. Schwacha, M. G., C. S. Chung, A. Ayala, K. I. Bland, and I. H. Chaudry. 2002. Cyclooxygenase 2-mediated suppression of macrophage interleukin-12 production after thermal injury. Am. J. Physiol. Cell Physiol. 282: C263-C270.
66. Shoup, M., L. K. He, H. Liu, R. Shankar, and R. Gamelli. 1998. Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection. J. Trauma 45:215-220, discussion 220-221.
67. Ipaktchi, K., A. Mattar, A. D. Niederbichler, L. M. Hoesel, S. Vollmannshauser, M. R. Hemmila, G. L. Su, D. G. Remick, S. C. Wang, and S. Arbabi. 2006. Attenuating burn wound inflammatory signaling reduces systemic inflammation and acute lung injury. J. Immunol. 177:8065-8071.
68. Ipaktchi, K., A. Mattar, A. D. Niederbichler, J. Kim, L. M. Hoesel, M. R. Hemmila, G. L. Su, D. G. Remick, S. C. Wang, and S. Arbabi. 2007. Attenuating burn wound inflammation improves pulmonary function and survival in a burn-pneumonia model. Crit. Care Med. 35:2139-2144.
69. Chen, X. L., Z. F. Xia, D. F. Ben, G. Q. Wang, and D. Wei. 2003. Role of p38 mitogen-activated protein kinase in lung injury after burn trauma. Shock 19:475-479.
70. Chen, L. W., W. J. Chang, J. S. Wang, and C. M. Hsu. 2007. Interleukin-1 mediates thermal injury-induced lung damage through C-Jun. NH2-terminal kinase signaling. Crit. Care Med. 35:1113-1122.
71. Chen, L. W., W. J. Chang, J. S. Wang, and C. M. Hsu. 2006. Thermal injuryinduced peroxynitrite production and pulmonary inducible nitric oxide synthase expression depend on JNK/AP-1 signaling. Crit. Care Med. 34:142-150.
72. Gan, H. T., P. J. Pasricha, and J. D. Chen. 2007. Blockade of p38 mitogenactivated protein kinase pathway ameliorates delayed intestinal transit in burned rats. Am. J. Surg. 193:530-537.
73. Alderliesten, M., M. de Graauw, J. Oldenampsen, Y. Qin, C. Pont, L. van Buren, and B. van de Water. 2007. Extracellular signal-regulated kinase activation during renal ischemia/reperfusion mediates focal adhesion dissolution and renal injury. Am. J. Pathol. 171:452-462.
74. Farrokhnia, N., A. Ericsson, A. Terént, and F. Lennmyr. 2008. MEK-inhibitor U0126 in hyperglycaemic focal ischaemic brain injury in the rat. Eur. J. Clin. Invest. 38:679-685.
75. Hsu, J. T., W. H. Kan, C. H. Hsieh, M. A. Choudhry, K. I. Bland, and I. H. Chaudry. 2009. Role of extracellular signal-regulated protein kinase (ERK) in 17b-estradiol-mediated attenuation of lung injury after trauma-hemorrhage. Surgery 145:226-234.
76. Ramnath, R. D., J. Sun, and M. Bhatia. 2009. Involvement of SRC family kinases in substance P-induced chemokine production in mouse pancreatic acinar cells and its significance in acute pancreatitis. J. Pharmacol. Exp. Ther. 329:418-428.
77. q-dependent pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L430-L437.
78. 2+-mediated neutrophil O responses with thermal injury. Am. J. Physiol. Cell Physiol. 283: C1469-C1479.